Table 3.
Monocyte SNP association with anti-cancer therapy effects.
| Therapy | Gene, SNP | Cancer type | Correlation | Reference |
|---|---|---|---|---|
| Surgery | TMEM176B rs2072443 (chr.7) | CRC (N=187) |
Higher OS | (248) |
| CT (FOLFIRI) + targeted therapy: (bevacizumab) |
CCL2 rs4586 (chr.17) | Metastatic CRC (N=424) |
Higher PFS | (249) |
| CT anthracyclines | TLR4 rs4986790 (chr.9) and rs4986791 (chr.9) | Breast cancer (N=47 and 111) |
Poor efficacy and early relapse | (250) |
| RT (60 Gy) + CT (Temozolomide) |
CCR2 rs1799864 (chr.9) or PTENP1 rs7853346 (chr.9) via lncRNA-PTENP1/miR-19b/CCR2 pathway |
Glioma (N=279) |
Alleviated cognitive impairment after treatment | (251) |
| RT (≧64.8 Gy) | CCL2 rs1024611(chr.17) | Nasopharyngeal carcinoma (N=411) |
AA and AG genotypes correlate with distant metastasis | (252) |
| IT: PD-1/PD-L1 checkpoint inhibitors |
Signature of CCL2 rs13900 (chr.17) and rs4586 (chr.17); NOS3 rs1799983 (chr.7); IL6R rs4845618 (chr.1); IL12B rs3212227 (chr.5); IL1RN rs419598 (chr.5); CXCR3 rs2280964 (chr.X) |
NSCLC, Renal cell carcinoma HNSCC Melanoma (n=94) |
Good response to anti-PD-1/PD-L1 treatment | (253) |
CRC, colorectal cancer; FOLFIR, folinic acid, fluorouracil and irinotecan; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung carcinoma; OS, overall survival; PFS, progression-free survival.